Retrospective Survey Evaluating the Effectiveness and Safety of Dual Inhibition Lipid-lowering in the Treatment of Dyslipidemia (Study P05171)(COMPLETED)
CompletedOBSERVATIONAL
Enrollment
1,200
Participants
Timeline
Start Date
May 31, 2007
Primary Completion Date
July 31, 2007
Study Completion Date
July 31, 2007
Conditions
Dyslipidemia
Interventions
DRUG
Ezetimibe 10 mg plus statin or ezetimibe 10 mg plus fenofibrate
Ezetimibe 10 mg taken daily for 3 months
All Listed Sponsors
lead
Organon and Co
INDUSTRY
NCT00726856 - Retrospective Survey Evaluating the Effectiveness and Safety of Dual Inhibition Lipid-lowering in the Treatment of Dyslipidemia (Study P05171)(COMPLETED) | Biotech Hunter | Biotech Hunter